Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Saroja Pharma Ind IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2019 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 84  to  84 per share
Profile
Min Investment ₹84
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Saroja Pharma Industries India Ltd is a prominent pharmaceutical company headquartered in India. Established with a commitment to advancing healthcare, Saroja Pharma specializes in the research, development, and production of high-quality pharmaceutical products. With a strong focus on innovation and quality assurance, the company has earned a reputation for delivering safe and effective medicines to patients worldwide. Saroja Pharma's state-of-the-art manufacturing facilities adhere to stringent global quality standards, ensuring the production of a diverse range of pharmaceutical formulations, including tablets, capsules, injectables, and more. The company's dedication to research and development has led to the creation of cutting-edge drugs, addressing various medical needs. Committed to improving global healthcare, Saroja Pharma Industries India Ltd continues to expand its presence in the pharmaceutical industry, contributing to the well-being of individuals through accessible and innovative healthcare solutions. Read More

Basic Info

Face Value 10 per share

Price 84  to  84 per share

P/E (x) 32.3

Sales( Cr.) 54

PAT( Cr.) 1

EPS 2.6

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Mr. Biju Gopinathan Nair Mr. Manish Dasharath Kamble

Pre Issue Share Holding 100%

Post Issue Share Holding 73.02%

Listing Details:

Listing Price: 65

Listing Gain: -29.23%

Current Price: 32.5

Gain On Issue: 32.5 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Aug 31, 2023
Closing Date Sep 05, 2023
Allotment Sep 06, 2023
Refund Sep 07, 2023
Delivery of Shares Sep 07, 2023
Listing Date Sep 08, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1600 134,400
Retail (Max) 1 1600 134,400
S-HNI (Min) 2 3200 268,800
S-HNI (Max) 7 11200 940,800
B-HNI (Min) 8 12800 1,075,200

Objective of the Issue

1. To Set-up a Manufacturing Unit. 2. To Repay the Unsecured Loans. 3. Public Issue Expenses.

Issue

Category Nos Bid Bid (x)
QIB 0 0 0x
NII 542400 1572960 2.9x
Retail 542400 8043792 14.8x
EMP 0 0 0x
Total 1084800 9633024 8.9x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Saroja Pharma Ind Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 37 56 50 41 54
Other Income 0 0 0 0 0
Total Income 37 56 50 41 54
Total Expenditure 35 54 47 38 51
Operating Profit 1 2 3 3 3
Interest 0 1 1 1 1
Depreciation 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 1 2 1 1 1
Provision for Tax 0 0 0 0 0
Profit After Tax 1 1 1 1 1
Adjustments 0 0 0 0 0
Profit After Adjustments 1 1 1 1 1
Adjusted Earnings Per Share 56.3 3.9 3.6 2.2 2.6

Saroja Pharma Ind Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1 4 5 15 16
Minority's Interest 0 0 0 0 0
Borrowings 1 2 3 3 1
Other Non-Current Liabilities 0 0 0 0 0
Total Current Liabilities 6 10 13 9 22
Total Liabilities 8 16 21 27 40
Fixed Assets 0 0 2 3 3
Other Non-Current Assets 0 0 3 6 10
Total Current Assets 8 15 16 18 27
Total Assets 8 16 21 27 40

Saroja Pharma Ind Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0
Cash Flow from Operating Activities -1 -4 2 1 1
Cash Flow from Investing Activities -0 -0 -5 -5 -3
Cash Flow from Financing Activities 1 4 3 4 2
Net Cash Inflow / Outflow -0 0 0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0 0

Saroja Pharma Ind Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 56.25 3.88 3.61 2.18 2.57
CEPS(Rs) 57.98 4.04 3.84 2.42 2.86
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) 71.99 13.72 17.33 36.42 38.99
Core EBITDA Margin(%) 3.56 3.78 5.42 6.29 5.19
EBIT Margin(%) 3.73 4.28 5.6 6.53 5.32
Pre Tax Margin(%) 2.82 2.84 2.97 2.97 2.7
PAT Margin (%) 1.99 2.05 2.11 2.16 1.92
Cash Profit Margin (%) 2.06 2.13 2.25 2.39 2.14
ROA(%) 8.89 9.61 5.76 3.67 3.13
ROE(%) 78.14 45.95 23.28 8.9 6.82
ROCE(%) 34.59 33.73 22.1 14.91 12.56
Receivable days 71.92 69.56 91.22 122.72 145.45
Inventory Days 6.53 3.68 15.75 19.13 1.69
Payable days 47.31 35.58 45.99 61.58 74.63
PER(x) 0 0 0 16.07 14.68
Price/Book(x) 0 0 0 0.96 0.97
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) 0.08 0.11 0.25 0.48 0.45
EV/Core EBITDA(x) 2.18 2.51 4.43 7.1 8.17
Net Sales Growth(%) 0 51.75 -9.78 -18.97 32.11
EBIT Growth(%) 0 74.15 18.05 -5.49 7.6
PAT Growth(%) 0 55.9 -6.97 -17.19 17.75
EPS Growth(%) 0 -93.1 -6.98 -39.53 17.75
Debt/Equity(x) 3.22 1.52 2 0.39 0.6
Current Ratio(x) 1.38 1.54 1.2 1.89 1.21
Quick Ratio(x) 1.27 1.49 0.91 1.85 1.21
Interest Cover(x) 4.12 2.97 2.13 1.83 2.03
Total Debt/Mcap(x) 0 0 0 0.41 0.62

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 32% -1% 0% 0%
Operating Profit CAGR 0% 14% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -22% NA% NA% NA%
ROE Average 7% 13% 33% 33%
ROCE Average 13% 17% 24% 24%

Company Contact Information

Saroja Pharma Industries India Ltd.

305, Kailash Tower, Shiv Shristi Complex Goregaon Link Road Mulund (West)

IPO Lead Manager(s)

Saroja Pharma Industries India Ltd.

Swastika Investmart Ltd.

Registrar Info

Saroja Pharma Industries India Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!